Best Fit Profiles
- experimental longevity protocols under medical supervision only
Senolytic therapy (senescent cell clearance)
Dasatinib
Dasatinib (a BCR-ABL inhibitor) combined with quercetin is being investigated as a senolytic regimen in early-phase human trials. Mayo Clinic studies show reduction in senescent cell burden. Still experimental outside oncology.
Evidence Level C
Evidence and Risk Labels
Evidence A/B/C reflects research maturity, and risk levels reflect monitoring needs. These labels support comparison, not diagnosis or treatment decisions.
See full scoring guideClinical Snapshot
- Effect Size
- Meaningful reduction in senescent cell markers in early trials; clinical outcomes not yet established
- Safety
- Needs Monitoring
Dasatinib is a prescription chemotherapy agent with significant side effect potential including pleural effusion, bleeding, and QT prolongation. Off-label use requires medical oversight.
Research Dosing
This reflects common ranges and protocols used in published studies, not personal medical advice.
- Typical Daily Dose
- 100 mg (dasatinib) + 1000 mg (quercetin), intermittent
- Timing
- 2-day intermittent pulse protocols used in trials
- Protocol Duration in Studies
- Experimental; quarterly or biannual pulses studied
Not for self-administration; requires prescribing physician and monitoring.